Image
Webinar Series

Trends and Updates in IBD

Appraising the Therapeutic Armamentarium in Moderate and Severe Disease

Suggested Readings

Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Colombel JF, et al. Lancet. 2018;390(10114):2779-2789.

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.

Coskun M, et al. Pharmacol Res. 2013;76:1-8.

Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies.

Kim DH, Cheon JH. Immune Netw. 2017;17(1):25-40.

The future of Janus kinase inhibitors in inflammatory bowel disease.

De Vries LCS, et al. J Crohns Colitis. 2017;11(7):885-893.

JAK inhibition in inflammatory bowel disease.

Olivera P, et al. Expert Rev Clin Immunol. 2017;13(7):693-703.

Tofacitinib as induction and maintenance therapy for ulcerative colitis.

Sandborn WJ, et al. N Engl J Med. 2017;377(5):496-497.

Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.

Vermeire S, et al. Lancet. 2017;389(10066):266-275.

Activity
Trends and Updates in IBD: Appraising the Therapeutic Armamentarium in Moderate and Severe Disease

Snapshot of IBD Today

Activity
Trends and Updates in IBD: Appraising the Therapeutic Armamentarium in Moderate and Severe Disease

The Current and Emerging Treatment Landscape of IBD

Relevant Resources

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis

Hepatitis C is Curable

Got it? Treat it!

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

The Nexus of NASH and Type 2 Diabetes Mellitus

The Emerging Role of the Diabetologist

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

The Changing Landscape of IBD

Emerging Concepts in Patient Management

The Big (& Small) Picture of Nonalcoholic Steatohepatitis

Building Your Understanding to Combat a Growing Problem

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

A Critical Appraisal of Non-Invasive Technologies in NASH

Informing the Future of NASH Diagnosis and Assessment

Setting a Course for the Optimal Management of IBD

An Interactive Learning Experience

Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up to Date?

A Focus on Clinical Evidence and Guideline Recommendations

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

IBD Journal Club:

Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients

Answering the Call

Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Putting a Spotlight on Systemic Mastocytosis

A Multidisciplinary Look at Early Diagnosis and Management

Is It Systemic Mastocytosis?

Best Practices for Diagnosis and Management

What’s Next

Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis